- Home
- GYRE vs RNP Comparison
GYRE vs RNP Comparison
Compare GYRE & RNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- RNP
- Stock Information
- Founded
- GYRE 2002
- RNP 2003
- Country
- GYRE United States
- RNP United States
- Employees
- GYRE N/A
- RNP N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- RNP Investment Managers
- Sector
- GYRE Health Care
- RNP Finance
- Exchange
- GYRE Nasdaq
- RNP Nasdaq
- Market Cap
- GYRE 1.1B
- RNP 1.0B
- IPO Year
- GYRE N/A
- RNP N/A
- Fundamental
- Price
- GYRE $10.95
- RNP $21.14
- Analyst Decision
- GYRE
- RNP
- Analyst Count
- GYRE 0
- RNP 0
- Target Price
- GYRE N/A
- RNP N/A
- AVG Volume (30 Days)
- GYRE 129.2K
- RNP 117.6K
- Earning Date
- GYRE 11-13-2024
- RNP 01-01-0001
- Dividend Yield
- GYRE N/A
- RNP 7.94%
- EPS Growth
- GYRE N/A
- RNP N/A
- EPS
- GYRE N/A
- RNP N/A
- Revenue
- GYRE $105,033,000.00
- RNP N/A
- Revenue This Year
- GYRE $25.32
- RNP N/A
- Revenue Next Year
- GYRE $12.95
- RNP N/A
- P/E Ratio
- GYRE N/A
- RNP N/A
- Revenue Growth
- GYRE N/A
- RNP N/A
- 52 Week Low
- GYRE $8.26
- RNP $15.52
- 52 Week High
- GYRE $26.37
- RNP $21.27
- Technical
- Relative Strength Index (RSI)
- GYRE 48.93
- RNP 49.40
- Support Level
- GYRE $9.51
- RNP $20.17
- Resistance Level
- GYRE $11.11
- RNP $21.11
- Average True Range (ATR)
- GYRE 0.85
- RNP 0.30
- MACD
- GYRE 0.04
- RNP 0.10
- Stochastic Oscillator
- GYRE 29.33
- RNP 89.81
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.